Table 1.

Protein accumulation levels of Immune checkpoint inhibitors (ICIs) Nivolumab, Monalizumab and Relatimab with an IgG4 S228P (IgG4P) Fc scaffold, as well as Nivolumab variable regions with an IgG1 L324A/L325A/P329G (Nivolumab IgG1AAG) scaffold. ICIs were expressed transiently with or without TBSV P19 silencing suppressor in N. benthamiana with WT glycosylation. Leaves were harvested at 6 dpi. Protein accumulation levels represent the mean, minimum and maximum of six biological repeats

ICI	Target	Protein accumulation level (g/kg LFW)
		Without P19	With P19
Nivo‐IgG4P	PD‐1	0.073 ± 0.007	0.770 ± 0.192
Nivo‐IgG1AAG	PD‐1	0.06 ± 0.01	0.557 ± 0.128
Monalizumab	NKG2A	0.02 ± 0.004	0.173 ± 0.090
Relatimab	LAG‐3	0.043 ± 0.005	0.416 ± 0.036